RS61927B1 - Farmaceutske supstance koje sadrže azd9291 - Google Patents
Farmaceutske supstance koje sadrže azd9291Info
- Publication number
- RS61927B1 RS61927B1 RS20210698A RSP20210698A RS61927B1 RS 61927 B1 RS61927 B1 RS 61927B1 RS 20210698 A RS20210698 A RS 20210698A RS P20210698 A RSP20210698 A RS P20210698A RS 61927 B1 RS61927 B1 RS 61927B1
- Authority
- RS
- Serbia
- Prior art keywords
- pharmaceutical
- substance
- parts
- agent
- shares
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1400034.3A GB201400034D0 (en) | 2014-01-02 | 2014-01-02 | Pharmaceutical Compositions comprising AZD9291 |
| EP15700082.9A EP3089741B1 (en) | 2014-01-02 | 2015-01-02 | Pharmaceutical compositions comprising azd9291 |
| PCT/GB2015/050001 WO2015101791A1 (en) | 2014-01-02 | 2015-01-02 | Pharmaceutical compositions comprising azd9291 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS61927B1 true RS61927B1 (sr) | 2021-06-30 |
Family
ID=50191689
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20210698A RS61927B1 (sr) | 2014-01-02 | 2015-01-02 | Farmaceutske supstance koje sadrže azd9291 |
Country Status (37)
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201400034D0 (en) * | 2014-01-02 | 2014-02-19 | Astrazeneca Ab | Pharmaceutical Compositions comprising AZD9291 |
| NO2699580T3 (cg-RX-API-DMAC7.html) | 2014-01-24 | 2018-02-24 | ||
| JP7030066B2 (ja) | 2016-05-26 | 2022-03-04 | リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー | Ｅｇｆｒ阻害剤化合物 |
| CN108057036B (zh) * | 2016-11-07 | 2023-06-13 | 正大天晴药业集团股份有限公司 | 一种egfr抑制剂的固体药物组合物 |
| CN107176954B (zh) * | 2017-06-02 | 2019-01-11 | 无锡双良生物科技有限公司 | 一种egfr抑制剂的药用盐及其晶型、制备方法和应用 |
| CN110013468B (zh) * | 2018-01-09 | 2022-02-18 | 北京福元医药股份有限公司 | 一种azd9291氘代衍生物药物制剂 |
| WO2019138346A1 (en) * | 2018-01-10 | 2019-07-18 | Alembic Pharmaceuticals Limited | Pharmaceutical composition of osimertinib |
| SG11202007414XA (en) | 2018-02-12 | 2020-09-29 | Astrazeneca Ab | Osimertinib for use in the treatment of non-small cell lung cancer |
| ES3011730T3 (en) * | 2018-03-01 | 2025-04-08 | Astrazeneca Ab | Pharmaceutical compositions comprising (2s)-{(1s)-1-cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide |
| EP3769764B1 (en) | 2018-03-23 | 2024-10-30 | Wuxi Shuangliang Biotechnology Co., Ltd. | Pharmaceutical composition and preparation method therefor and uses thereof |
| EP3823627A4 (en) | 2018-07-17 | 2022-04-20 | Insmed Incorporated | CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES FOR THE TREATMENT OF LUPUS ENEHROPATHY |
| KR20200043618A (ko) | 2018-10-18 | 2020-04-28 | 주식회사유한양행 | 아미노피리미딘 유도체 또는 이의 염을 포함하는 경구투여용 약학 조성물 |
| AU2020250832A1 (en) | 2019-03-29 | 2021-11-11 | Astrazeneca Ab | Osimertinib for use in the treatment of non-small cell lung cancer |
| US20210161897A1 (en) | 2019-11-12 | 2021-06-03 | Astrazeneca Ab | Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer |
| CN114980883A (zh) | 2020-01-20 | 2022-08-30 | 阿斯利康(瑞典)有限公司 | 用于治疗癌症的表皮生长因子受体酪氨酸激酶抑制剂 |
| US20210369709A1 (en) | 2020-05-27 | 2021-12-02 | Astrazeneca Ab | EGFR TKIs FOR USE IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER |
| TW202304457A (zh) * | 2021-03-22 | 2023-02-01 | 瑞典商阿斯特捷利康公司 | 配製物 |
| AU2023246862A1 (en) | 2022-03-31 | 2024-10-31 | Astrazeneca Ab | Epidermal growth factor receptor (egfr) tyrosine kinase inhibitors in combination with an akt inhibitor for the treatment of cancer |
| WO2023209086A1 (en) | 2022-04-28 | 2023-11-02 | Astrazeneca Ab | Bicyclic heteroaromatic compounds for treating cancer |
| WO2023209090A1 (en) | 2022-04-28 | 2023-11-02 | Astrazeneca Ab | Bicyclic heteroaromatic compounds and their application in the treatment of cancer |
| WO2023209088A1 (en) | 2022-04-28 | 2023-11-02 | Astrazeneca Ab | Bicyclic heteroaromatic compounds and their use in the treatment of cancer |
| CA3249080A1 (en) | 2022-04-28 | 2023-11-02 | Astrazeneca Ab | CONDENSED BICYCLIC HETEROAROMATIC COMPOUNDS AND THEIR USE IN CANCER TREATMENT |
| KR20250029133A (ko) | 2022-06-27 | 2025-03-04 | 아스트라제네카 아베 | 암 치료를 위한 표피성장인자 수용체 티로신 키나제 억제제를 포함하는 조합물 |
| WO2024008929A1 (en) | 2022-07-08 | 2024-01-11 | Astrazeneca Ab | Epidermal growth factor receptor tyrosine kinase inhibitors in combination with hgf-receptor inhibitors for the treatment of cancer |
| WO2024148308A1 (en) | 2023-01-06 | 2024-07-11 | Insmed Incorporated | Novel, reversible dpp1 inhibitors and uses thereof |
| WO2025092926A1 (zh) * | 2023-10-31 | 2025-05-08 | 浙江同源康医药股份有限公司 | 一种嘧啶类衍生物的药物组合物 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL110376A (en) * | 1993-08-02 | 1998-08-16 | Bristol Myers Squibb Co | Pharmaceutical compositions containing ifetroban salts and methods for the preparation thereof |
| SE9802973D0 (sv) * | 1998-09-03 | 1998-09-03 | Astra Ab | Immediate release tablet |
| AU2001248751A1 (en) * | 2000-04-12 | 2001-10-23 | Banyu Pharmaceutical Co. Ltd. | Compositions disintegrating in oral cavity and preparations disintegrating in oral cavity |
| US6881737B2 (en) | 2001-04-11 | 2005-04-19 | Amgen Inc. | Substituted triazinyl acrylamide derivatives and methods of use |
| EP1480679B1 (en) | 2002-02-26 | 2007-05-23 | Astrazeneca AB | Pharmaceutical formulation of iressa comprising a water-soluble cellulose derivative |
| JP2008515786A (ja) * | 2004-10-05 | 2008-05-15 | ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング | プロトンポンプアンタゴニスト用の経口医薬調剤 |
| ES2279715B1 (es) * | 2005-12-26 | 2008-06-01 | Laboratorios Lesvi, S.L. | Formulacion oral de olanzapina. |
| CN101415422B (zh) * | 2006-02-09 | 2012-11-07 | 第一三共株式会社 | 抗癌药用组合物 |
| JP5576922B2 (ja) * | 2006-04-20 | 2014-08-20 | 信越化学工業株式会社 | 腸溶性固体分散体を含んでなる固形製剤 |
| JP2010533205A (ja) * | 2007-07-12 | 2010-10-21 | トラガラ ファーマシューティカルズ，インク． | 癌、腫瘍、および腫瘍関連障害を治療するための方法および組成物 |
| WO2012139736A1 (en) | 2011-04-11 | 2012-10-18 | Alfred E. Tiefenbacher (Gmbh & Co. Kg) | Pharmaceutical composition comprising bosentan |
| KR101317809B1 (ko) | 2011-06-07 | 2013-10-16 | 한미약품 주식회사 | 암세포의 성장을 억제하는 아마이드 유도체 및 비금속염 활택제를 포함하는 약학 조성물 |
| DK3686194T3 (da) * | 2011-07-27 | 2021-11-22 | Astrazeneca Ab | 2-(2,4,5-substitueret-anilino)pyrimidinforbindelser |
| PL2802314T3 (pl) * | 2012-01-13 | 2021-06-14 | Xspray Microparticles Ab | Sposób wytwarzania stabilnych, amorficznych hybrydowych nanocząstek zawierających co najmniej jeden inhibitor kinazy białkowej i co najmniej jeden polimerowy składnik stabilizujący i tworzący macierz |
| WO2013160916A1 (en) | 2012-04-25 | 2013-10-31 | Hetero Research Foundation | Sunitinib malate solid dispersion |
| GB201400034D0 (en) * | 2014-01-02 | 2014-02-19 | Astrazeneca Ab | Pharmaceutical Compositions comprising AZD9291 |
-
2014
- 2014-01-02 GB GBGB1400034.3A patent/GB201400034D0/en not_active Ceased
- 2014-12-29 UY UY0001035933A patent/UY35933A/es not_active Application Discontinuation
- 2014-12-29 AR ARP140104947A patent/AR098989A1/es not_active Application Discontinuation
- 2014-12-31 TW TW103146652A patent/TWI702953B/zh active
-
2015
- 2015-01-02 HU HUE15700082A patent/HUE054344T2/hu unknown
- 2015-01-02 MY MYPI2016702433A patent/MY183536A/en unknown
- 2015-01-02 LT LTEP15700082.9T patent/LT3089741T/lt unknown
- 2015-01-02 SG SG11201605339QA patent/SG11201605339QA/en unknown
- 2015-01-02 JP JP2016544368A patent/JP6588915B2/ja active Active
- 2015-01-02 MX MX2016008744A patent/MX367358B/es active IP Right Grant
- 2015-01-02 SI SI201531610T patent/SI3089741T1/sl unknown
- 2015-01-02 EA EA201691242A patent/EA034243B9/ru not_active IP Right Cessation
- 2015-01-02 EP EP15700082.9A patent/EP3089741B1/en active Active
- 2015-01-02 CA CA2933403A patent/CA2933403C/en active Active
- 2015-01-02 WO PCT/GB2015/050001 patent/WO2015101791A1/en not_active Ceased
- 2015-01-02 AU AU2015204218A patent/AU2015204218B2/en active Active
- 2015-01-02 KR KR1020167020731A patent/KR102336378B1/ko active Active
- 2015-01-02 NZ NZ721298A patent/NZ721298A/en unknown
- 2015-01-02 PT PT157000829T patent/PT3089741T/pt unknown
- 2015-01-02 CR CR20160310A patent/CR20160310A/es unknown
- 2015-01-02 CN CN201580003266.4A patent/CN105848647B/zh active Active
- 2015-01-02 US US15/109,170 patent/US10183020B2/en active Active
- 2015-01-02 PE PE2016000943A patent/PE20161170A1/es unknown
- 2015-01-02 HR HRP20210749TT patent/HRP20210749T1/hr unknown
- 2015-01-02 CN CN202210324141.3A patent/CN114712362A/zh active Pending
- 2015-01-02 SM SM20210330T patent/SMT202100330T1/it unknown
- 2015-01-02 ES ES15700082T patent/ES2873226T3/es active Active
- 2015-01-02 PH PH1/2016/501310A patent/PH12016501310B1/en unknown
- 2015-01-02 RS RS20210698A patent/RS61927B1/sr unknown
- 2015-01-02 PL PL15700082T patent/PL3089741T3/pl unknown
- 2015-01-02 DK DK15700082.9T patent/DK3089741T3/da active
-
2016
- 2016-06-13 IL IL246186A patent/IL246186B/en active IP Right Grant
- 2016-06-22 CL CL2016001609A patent/CL2016001609A1/es unknown
- 2016-06-22 DO DO2016000156A patent/DOP2016000156A/es unknown
- 2016-06-29 GT GT201600142A patent/GT201600142A/es unknown
- 2016-07-01 NI NI201600098A patent/NI201600098A/es unknown
- 2016-08-01 ZA ZA2016/05300A patent/ZA201605300B/en unknown
-
2018
- 2018-11-20 US US16/196,185 patent/US20190111057A1/en not_active Abandoned
-
2020
- 2020-08-04 US US16/984,276 patent/US20200360378A1/en not_active Abandoned
-
2021
- 2021-06-08 CY CY20211100499T patent/CY1124848T1/el unknown
- 2021-09-17 US US17/478,117 patent/US20240189310A1/en not_active Abandoned
-
2022
- 2022-04-26 US US17/729,162 patent/US20220395502A1/en not_active Abandoned
-
2024
- 2024-09-26 US US18/897,609 patent/US20250017930A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250017930A1 (en) | Pharmaceutical compositions comprising azd9291 | |
| AU2014225449B2 (en) | Stabilization of moisture-sensitive drugs | |
| KR102197465B1 (ko) | 디메틸푸마르산염을 함유한 장용성 정제 | |
| EA030433B1 (ru) | Энтеросолюбильная таблетка | |
| EP2701689B1 (en) | Pharmaceutical compositions of raltegravir, methods of preparation and use thereof | |
| WO2021074808A1 (en) | Pharmaceutical composition comprising sacubitril and valsartan and process for preparation thereof | |
| Kestur et al. | Excipients for conventional oral solid dosage forms | |
| WO2021106004A1 (en) | Pharmaceutical composition of s-adenosylmethionine | |
| EP3796908A1 (en) | Controlled release propiverine formulations | |
| HK1228245B (en) | Pharmaceutical compositions comprising azd9291 | |
| JP6903252B2 (ja) | キサンチンオキシダーゼ阻害剤含有腸溶性製剤 | |
| HK1225655B (en) | Pharmaceutical compositions comprising azd9291 | |
| Kestur et al. | EXCIPIENTS ORAL SOLID FOR DOSAGE CONVENTIONAL FORMS | |
| BR112016014348B1 (pt) | Composição farmacêutica, uso da dita composição, comprimido farmacêutico e uso do dito comprimido | |
| JP2008162949A (ja) | チアゾリジンジオン化合物を含有する糖尿病治療薬 |